Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Boehringer Ingelheim announced the launch of once-daily Striverdi Respimat (olodaterol) 5mcg inhalation spray for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Striverdi Respimat is a long-acting beta-adrenergic agonist (LABA) that helps muscles around the airways in the lungs stay relaxed to prevent symptoms. It works by binding and activating beta2-adrenoceptors after topical administration by inhalation. Activation of these receptors in the airways results in a stimulation of intracellular adenyl cyclase, an enzyme that mediates the synthesis of cyclic-3′, 5′ adenosine monophosphate (cAMP). Elevated levels of cAMP induce bronchodilation by relaxation of airway smooth muscle cells.
RELATED: How Obesity and Diet Impact COPD
Striverdi Respimat is available in a carton containing a single cartridge for use with the Striverdi Respimat Inhaler. Each inhaler contains 60 metered actuations delivering 2.5mcg olodateral per actuation.
For more information call (800) 459-9906 or visit US.Boehringer-Ingelheim.com.
